INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
EXPERT VIEW
EXPERT VIEW
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
Chris Hurlstone looks at the process of developing drug delivery systems through the industrialisation phase and explores ways to address the challenges that arise along the way. Drawing on Team’s 40-year track record of supporting drug delivery device innovation, the insights are intended for teams involved in developing drug delivery systems, particularly those responsible for design, engineering, industrialisation and manufacturing transfer.
EXPERT VIEW
DE-RISKING POST-MARKET CHANGE THROUGH PILOT PRODUCTION
Jon Powell explores how pilot production, delivered through integrated design, development and manufacturing capabilities, can be used to de-risk change in commercial-scale drug delivery devices, highlighting how such approaches can improve confidence in decision-making while reducing overall time and cost.
EXPERT VIEW
John Ward
THE HIDDEN RISKS IN DRUG-DEVICE DELIVERY: WHY THE FINAL STAGE DEFINES LAUNCH SUCCESS
John Ward and Paul Hamill explore the structural and operational risks embedded in late-stage drug-device delivery, why these risks are intensifying and how the industry is beginning to rethink its approach to downstream execution.
EXPERT VIEW
Stephan Vogel
EFFICIENCY, DATA INTEGRITY AND QUALITY ASSURANCE IN THE PRODUCTION OF INSULIN PENS
Stephan Vogel discusses the role of advanced monitoring technologies in high-volume medical device manufacturing, considering the key role they play in ensuring quality and compliance with regulatory requirements and how analysing data centrally can support consistency across lines and sites.
EXPERT VIEW
Dr Sahab Babaee
ORAL DELIVERY OF MACROMOLECULES: CHALLENGES AND OPPORTUNITIES FOR DEVICE-ENABLED GI DELIVERY
Dr Sahab Babaee discusses the potential of device-based approaches to enable the delivery of macromolecules via the gastrointestinal tract, considering the constraints and possibilities of mucosal delivery devices, as well as the technologies currently being investigated to make this potential a reality.
EXPERT VIEW
Leo Pan
TRANSDERMAL DRUG DELIVERY: ENHANCING PERMEABILITY AND IN VIVO TRANSLATION
Dr Leo Pan provides insights into the field of transdermal drug delivery and investigates the two primary approaches being taken to advance the sector – enhancing the ability of drugs to permeate through the skin barrier and translating in vitro data to an in vivo reality.
EXPERT VIEW
Dr Mehul Desai
ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION
Dr Mehul Desai, Dr Michael Hageman and Dr Wei Chen examine the growing antibody-drug conjugate market, the unique formulation challenges these therapies present for subcutaneous delivery and how innovations in on-body injector technology may offer a practical path forwards.
EXPERT VIEW
Norbert Kübler
STERILE DRUG PRODUCTION: AN EVER-EVOLVING MARKET
Dr Norbert Kübler discusses the current state of sterile drug products, considering how advancing technology is changing the field, the role of quality control and the challenges faced during scale-up and manufacturing.
EXPERT VIEW
Henryk Badack
MAINTAINING RELIABLE DRUG DELIVERY THROUGH SUSTAINABLE OPERATIONS
Henryk Badack considers how a holistic approach to sustainability can enable CDMOs to implement efficient operations strategically – while introducing initiatives that address environmental, economic and social elements.
EXPERT VIEW
Kiara Taylor
LATE-STAGE MATERIAL SUBSTITUTION: AMBITION FOR SUSTAINABILITY OR TRANSFER-TIME RISK?
Kiara Taylor delves into the challenges of changing materials to enhance sustainability after a design has been transferred to manufacturing, considering the reasons that might drive such a change, the issues involved and the benefits that can be gained.
EXPERT VIEW
Adam Tilley
SUSTAINABILITY IN DRUG DELIVERY
Adam Tilley and David Cook explore how carbon footprint considerations can be integrated into the drug delivery device design lifecycle, highlighting key sustainability decisions faced by design engineers and emerging tools that support those evaluations.
EXPERT VIEW
Greg Anderson
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.
EXPERT VIEW
Markus Laubscher
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
EXPERT VIEW
Gregg Draudt
INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?
Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.
EXPERT VIEW
Tina Rogers
WuXi AppTec
ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT
Dr Tina Rogers discusses antibody-drug conjugates and their potential in direct targeting and treatment of cancers, going further to assess the risks of these treatments and how they can be mitigated.
EXPERT VIEW
Tom Oakley
TRENDS FOR 2026
A new reality is forming as we enter 2026 – it will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the US, are likely to mean substantial changes. Here, Tom Oakley and Alex Vasiev cover those changes, the incretin juggernaut and the march of technical progress with “minitablet” dispensers, large-volume injectors and dual-chamber devices.
EXPERT VIEW
Dr Oliver Eden
DEVELOPMENTAL ADVANTAGES IN INJECTABLE COMBINATION DRUG PRODUCTS
Oliver Eden and Travis Webb consider how regulatory considerations and patient-centric device designs are transforming the landscape of self-administered injectable drugs.
EXPERT VIEW
Angela Shotton
DESIGNING SUSTAINABLE DRUG DELIVERY DEVICE PACKAGING: TRENDS, CHALLENGES AND REGULATORY IMPLICATIONS
Angela Shotton and Nic Hunt, look at the evolving landscape of the pharmaceutical packaging landscape and consider how the industry is meeting sustainability and regulatory requirements.
EXPERT VIEW
Paul Jansen
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
Drawing on his extensive experience in the drug delivery device industry, Paul Jansen considers how funding for delivery device development has shifted over the years, from the pre-platform model to currently accepted practice and looks forward to how it may further evolve to support the development of novel devices in the biologics space and beyond.
EXPERT VIEW
Tim Quigg
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
Tim Quigg, Mariam Al-Amari and Joel Gresham discuss how to enable high-dose delivery for novel biologics, using
ex vivo
and
in silico
approaches to accelerate drug-device development and improve device performance, thus de-risking projects and saving costs.
EXPERT VIEW
Dr Fiona McLaughlin
IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY
Dr Fiona McLaughlin and Dr Mark Edbrooke discuss the possibilities for developing novel cancer treatments using functionalised nanoparticles, in order to transport a variety of therapies into the tumour microenvironment.
EXPERT VIEW
Dr Max Chambers
REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY
Dr Max Chambers discusses novel approaches for delivering ocular gene therapies, summarising the challenges and benefits of various delivery routes and exploring the devices used to successfully improve vision.
EXPERT VIEW
Bharat Arora
DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS
Bharat Arora discusses how the delivery method for a cell and gene therapy is an integral part of the overall product, inextricable from the therapy itself, and how properly synchronising drug and delivery device development can greatly benefit the overall development programme.
EXPERT VIEW
Dr Akshay Peer
CELL AND GENE THERAPY DIGITAL INFRASTRUCTURE: REPLACING FRAGMENTATION WITH STANDARDISATION
Dr Akshay Peer examines why bespoke digital systems for cell and gene therapies are reaching a saturation point, how clinicians experience this fragmentation on the ground and why a shift towards standardisation is becoming essential for enabling safe, scalable and sustainable delivery of these innovative treatments.
EXPERT VIEW
Dr Elodie Bovier
MAPPING INNOVATION IN mRNA DELIVERY THROUGH PATENT TRENDS
Dr Elodie Bovier considers the evolution of messenger RNA therapeutics in biotechnology, examining patent trends and exploring how they have triggered litigation in the field, demonstrating the growth and maturity of this sector.
1
2
3
…
15
Next
Top
